Tenofovir disoproxil fumarate and bone mineral density: A 60-month longitudinal study in a cohort of HIV-infected youths

Alessandra Viganò, Gian V. Zuccotti, Maria Puzzovio, Valentina Pivetti, Ilaria Zamproni, Chiara Cerini, Valentina Fabiano, Vania Giacomet, Stefano Mora

Research output: Contribution to journalArticle

Abstract

Background: Decreased bone mineral density (BMD) has been associated with the use of tenofovir disoproxil fumarate (TDF) in HIV-infected adults. The data in HIV-infected children are conflicting. The aim of this study was to assess the safety of a TDF-containing antiretroviral (ARV) regimen on BMD in paediatric patients. We report the results of a longitudinal 60-month follow-up study. Methods: A total of 21 vertically HIV-infected Caucasian youths (10 male and 11 female) on ARV treatment containing lamivudine, efavirenz and TDF were enrolled (age range 4.9-17.9 years at baseline). BMD was measured at the lumbar spine and in the whole skeleton by DXA. Bone-specific alkaline phosphatase (BAP) was measured as a bone formation marker and urinary N-telopeptide of type-I collagen (NTx) was measured as a bone resorption index. Results: Baseline mean (±sd) BMD measurements of HIV-infected patients expressed as z-scores were -0.7 (±0.9) for lumbar spine and -0.13 (±1.0) for the whole skeleton. BMD measurements did not change significantly during the 60-month observation period. Both BAP and NTx concentrations were higher than a reference group of controls at baseline and remained unchanged throughout the study. Conclusions: Our data indicate that a TDF-containing regimen does not decrease the BMD of HIV-infected youths.

Original languageEnglish
Pages (from-to)1053-1058
Number of pages6
JournalAntiviral Therapy
Volume15
Issue number7
DOIs
Publication statusPublished - 2010

Fingerprint

Tenofovir
Bone Density
Longitudinal Studies
HIV
efavirenz
Skeleton
Alkaline Phosphatase
Spine
Bone and Bones
Lamivudine
Bone Resorption
Collagen Type I
Osteogenesis
Observation

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Tenofovir disoproxil fumarate and bone mineral density : A 60-month longitudinal study in a cohort of HIV-infected youths. / Viganò, Alessandra; Zuccotti, Gian V.; Puzzovio, Maria; Pivetti, Valentina; Zamproni, Ilaria; Cerini, Chiara; Fabiano, Valentina; Giacomet, Vania; Mora, Stefano.

In: Antiviral Therapy, Vol. 15, No. 7, 2010, p. 1053-1058.

Research output: Contribution to journalArticle

Viganò, A, Zuccotti, GV, Puzzovio, M, Pivetti, V, Zamproni, I, Cerini, C, Fabiano, V, Giacomet, V & Mora, S 2010, 'Tenofovir disoproxil fumarate and bone mineral density: A 60-month longitudinal study in a cohort of HIV-infected youths', Antiviral Therapy, vol. 15, no. 7, pp. 1053-1058. https://doi.org/10.3851/IMP1650
Viganò, Alessandra ; Zuccotti, Gian V. ; Puzzovio, Maria ; Pivetti, Valentina ; Zamproni, Ilaria ; Cerini, Chiara ; Fabiano, Valentina ; Giacomet, Vania ; Mora, Stefano. / Tenofovir disoproxil fumarate and bone mineral density : A 60-month longitudinal study in a cohort of HIV-infected youths. In: Antiviral Therapy. 2010 ; Vol. 15, No. 7. pp. 1053-1058.
@article{bd6a18d0d19741279b361f6b55eee41c,
title = "Tenofovir disoproxil fumarate and bone mineral density: A 60-month longitudinal study in a cohort of HIV-infected youths",
abstract = "Background: Decreased bone mineral density (BMD) has been associated with the use of tenofovir disoproxil fumarate (TDF) in HIV-infected adults. The data in HIV-infected children are conflicting. The aim of this study was to assess the safety of a TDF-containing antiretroviral (ARV) regimen on BMD in paediatric patients. We report the results of a longitudinal 60-month follow-up study. Methods: A total of 21 vertically HIV-infected Caucasian youths (10 male and 11 female) on ARV treatment containing lamivudine, efavirenz and TDF were enrolled (age range 4.9-17.9 years at baseline). BMD was measured at the lumbar spine and in the whole skeleton by DXA. Bone-specific alkaline phosphatase (BAP) was measured as a bone formation marker and urinary N-telopeptide of type-I collagen (NTx) was measured as a bone resorption index. Results: Baseline mean (±sd) BMD measurements of HIV-infected patients expressed as z-scores were -0.7 (±0.9) for lumbar spine and -0.13 (±1.0) for the whole skeleton. BMD measurements did not change significantly during the 60-month observation period. Both BAP and NTx concentrations were higher than a reference group of controls at baseline and remained unchanged throughout the study. Conclusions: Our data indicate that a TDF-containing regimen does not decrease the BMD of HIV-infected youths.",
author = "Alessandra Vigan{\`o} and Zuccotti, {Gian V.} and Maria Puzzovio and Valentina Pivetti and Ilaria Zamproni and Chiara Cerini and Valentina Fabiano and Vania Giacomet and Stefano Mora",
year = "2010",
doi = "10.3851/IMP1650",
language = "English",
volume = "15",
pages = "1053--1058",
journal = "Antiviral Therapy",
issn = "1359-6535",
publisher = "International Medical Press Ltd",
number = "7",

}

TY - JOUR

T1 - Tenofovir disoproxil fumarate and bone mineral density

T2 - A 60-month longitudinal study in a cohort of HIV-infected youths

AU - Viganò, Alessandra

AU - Zuccotti, Gian V.

AU - Puzzovio, Maria

AU - Pivetti, Valentina

AU - Zamproni, Ilaria

AU - Cerini, Chiara

AU - Fabiano, Valentina

AU - Giacomet, Vania

AU - Mora, Stefano

PY - 2010

Y1 - 2010

N2 - Background: Decreased bone mineral density (BMD) has been associated with the use of tenofovir disoproxil fumarate (TDF) in HIV-infected adults. The data in HIV-infected children are conflicting. The aim of this study was to assess the safety of a TDF-containing antiretroviral (ARV) regimen on BMD in paediatric patients. We report the results of a longitudinal 60-month follow-up study. Methods: A total of 21 vertically HIV-infected Caucasian youths (10 male and 11 female) on ARV treatment containing lamivudine, efavirenz and TDF were enrolled (age range 4.9-17.9 years at baseline). BMD was measured at the lumbar spine and in the whole skeleton by DXA. Bone-specific alkaline phosphatase (BAP) was measured as a bone formation marker and urinary N-telopeptide of type-I collagen (NTx) was measured as a bone resorption index. Results: Baseline mean (±sd) BMD measurements of HIV-infected patients expressed as z-scores were -0.7 (±0.9) for lumbar spine and -0.13 (±1.0) for the whole skeleton. BMD measurements did not change significantly during the 60-month observation period. Both BAP and NTx concentrations were higher than a reference group of controls at baseline and remained unchanged throughout the study. Conclusions: Our data indicate that a TDF-containing regimen does not decrease the BMD of HIV-infected youths.

AB - Background: Decreased bone mineral density (BMD) has been associated with the use of tenofovir disoproxil fumarate (TDF) in HIV-infected adults. The data in HIV-infected children are conflicting. The aim of this study was to assess the safety of a TDF-containing antiretroviral (ARV) regimen on BMD in paediatric patients. We report the results of a longitudinal 60-month follow-up study. Methods: A total of 21 vertically HIV-infected Caucasian youths (10 male and 11 female) on ARV treatment containing lamivudine, efavirenz and TDF were enrolled (age range 4.9-17.9 years at baseline). BMD was measured at the lumbar spine and in the whole skeleton by DXA. Bone-specific alkaline phosphatase (BAP) was measured as a bone formation marker and urinary N-telopeptide of type-I collagen (NTx) was measured as a bone resorption index. Results: Baseline mean (±sd) BMD measurements of HIV-infected patients expressed as z-scores were -0.7 (±0.9) for lumbar spine and -0.13 (±1.0) for the whole skeleton. BMD measurements did not change significantly during the 60-month observation period. Both BAP and NTx concentrations were higher than a reference group of controls at baseline and remained unchanged throughout the study. Conclusions: Our data indicate that a TDF-containing regimen does not decrease the BMD of HIV-infected youths.

UR - http://www.scopus.com/inward/record.url?scp=78651094152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78651094152&partnerID=8YFLogxK

U2 - 10.3851/IMP1650

DO - 10.3851/IMP1650

M3 - Article

C2 - 21041922

AN - SCOPUS:78651094152

VL - 15

SP - 1053

EP - 1058

JO - Antiviral Therapy

JF - Antiviral Therapy

SN - 1359-6535

IS - 7

ER -